FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379336031> ?p ?o ?g. }

• W4379336031 endingPage "e16582" @default.
• W4379336031 startingPage "e16582" @default.
• W4379336031 abstract "e16582 Background: Response rates with ICI are modest at around 20% in mUC and there is a lack of validated biomarkers to select pts who are likely to derive benefit from ICI. There is an unmet need to develop biomarkers of response and resistance to avoid unnecessary treatment (Tx) and spare physical and financial toxicity. Here we report tumor immune-genomic characteristics associated with response and resistance to ICI in mUC. Methods: We selected 58 mUC pts who received at least 2 cycles of ICI (atezolizumab or pembrolizumab) between 2015-2020 and had pre-Tx archival formalin fixed paraffin-embedded (FFPE) tissues available. Pts were categorized by their response to ICI as responders (R) (Complete Response (CR), Partial Response (PR), and Stable Disease (SD)) (N = 30) or non-responders (NR) (Progressive Disease (PD)) (N = 28). Tumor was macrodissected from FFPE slides and RNA extraction was done using Qiagen Rneasy FFPE kit. 100ng of RNA was used for transcriptomic analysis using the Nanostring PanCancer IO 360 panel. Data normalization and analysis was carried out using nSolver 4.0. Results: Differential expression analysis comparing (R) vs (NR) displayed upregulation of gene signatures associated with Immunoproteasome, Antigen presenting machinery (APM), IFN Gamma, PD-L1, and IFN downstream. Additionally, the tumor inflammation signature (TIS), which is trained to predict response to ICI, was upregulated in (R) vs (NR) (Table 1). Single gene analysis showed trend towards upregulation of ISG15 (logFC = 0.7821, p = 0.00337), TAP1(logFC = 0.7649, p = 0.00422), and STAT1 (logFC = 0.6053, p = 0.00510) in (R), P-values, were above significance threshold after adjustment for multiple comparisons. Receiver operator characteristic (ROC) analysis with area-under the curve (AUC) scores assess capacity of gene signatures to predict response to ICI (Table 1). In our cohort, the median overall survival for (R) was 44.1 months compared to 24.5 months in NR (p = 0.0100). Conclusions: In our cohort of mUC pts treated with ICI, we found an association between signatures of tumor immunogenicity (APM and Immunoproteosome) and anti-tumor immune activity (IFN Gamma, IFN Downstream, TIS) in pre-Tx tissue with favorable response to therapy (including SD). These findings are hypothesis generating and need to be further validated in prospective trials. Ongoing genomic and immunologic correlative studies in our cohort will further help understand comprehensive biomarkers of response and resistance to ICI in pts with mUC. [Table: see text]" @default.
• W4379336031 created "2023-06-05" @default.
• W4379336031 creator A5004894140 @default.
• W4379336031 creator A5022753685 @default.
• W4379336031 creator A5024482335 @default.
• W4379336031 creator A5031016267 @default.
• W4379336031 creator A5034605162 @default.
• W4379336031 creator A5042184224 @default.
• W4379336031 creator A5043906360 @default.
• W4379336031 creator A5044873389 @default.
• W4379336031 creator A5060948890 @default.
• W4379336031 creator A5070192160 @default.
• W4379336031 creator A5072435293 @default.
• W4379336031 creator A5079075086 @default.
• W4379336031 creator A5085980531 @default.
• W4379336031 creator A5092084946 @default.
• W4379336031 date "2023-06-01" @default.
• W4379336031 modified "2023-10-18" @default.
• W4379336031 title "Characterizing immune-genomic signatures associated with response to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC)." @default.
• W4379336031 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e16582" @default.
• W4379336031 hasPublicationYear "2023" @default.
• W4379336031 type Work @default.
• W4379336031 citedByCount "0" @default.
• W4379336031 crossrefType "journal-article" @default.
• W4379336031 hasAuthorship W4379336031A5004894140 @default.
• W4379336031 hasAuthorship W4379336031A5022753685 @default.
• W4379336031 hasAuthorship W4379336031A5024482335 @default.
• W4379336031 hasAuthorship W4379336031A5031016267 @default.
• W4379336031 hasAuthorship W4379336031A5034605162 @default.
• W4379336031 hasAuthorship W4379336031A5042184224 @default.
• W4379336031 hasAuthorship W4379336031A5043906360 @default.
• W4379336031 hasAuthorship W4379336031A5044873389 @default.
• W4379336031 hasAuthorship W4379336031A5060948890 @default.
• W4379336031 hasAuthorship W4379336031A5070192160 @default.
• W4379336031 hasAuthorship W4379336031A5072435293 @default.
• W4379336031 hasAuthorship W4379336031A5079075086 @default.
• W4379336031 hasAuthorship W4379336031A5085980531 @default.
• W4379336031 hasAuthorship W4379336031A5092084946 @default.
• W4379336031 hasConcept C104317684 @default.
• W4379336031 hasConcept C121608353 @default.
• W4379336031 hasConcept C126322002 @default.
• W4379336031 hasConcept C127561419 @default.
• W4379336031 hasConcept C143998085 @default.
• W4379336031 hasConcept C150194340 @default.
• W4379336031 hasConcept C162317418 @default.
• W4379336031 hasConcept C203014093 @default.
• W4379336031 hasConcept C2775949291 @default.
• W4379336031 hasConcept C2777701055 @default.
• W4379336031 hasConcept C2780057760 @default.
• W4379336031 hasConcept C2780352672 @default.
• W4379336031 hasConcept C2911057145 @default.
• W4379336031 hasConcept C3019882237 @default.
• W4379336031 hasConcept C502942594 @default.
• W4379336031 hasConcept C55493867 @default.
• W4379336031 hasConcept C71924100 @default.
• W4379336031 hasConcept C86803240 @default.
• W4379336031 hasConcept C8891405 @default.
• W4379336031 hasConceptScore W4379336031C104317684 @default.
• W4379336031 hasConceptScore W4379336031C121608353 @default.
• W4379336031 hasConceptScore W4379336031C126322002 @default.
• W4379336031 hasConceptScore W4379336031C127561419 @default.
• W4379336031 hasConceptScore W4379336031C143998085 @default.
• W4379336031 hasConceptScore W4379336031C150194340 @default.
• W4379336031 hasConceptScore W4379336031C162317418 @default.
• W4379336031 hasConceptScore W4379336031C203014093 @default.
• W4379336031 hasConceptScore W4379336031C2775949291 @default.
• W4379336031 hasConceptScore W4379336031C2777701055 @default.
• W4379336031 hasConceptScore W4379336031C2780057760 @default.
• W4379336031 hasConceptScore W4379336031C2780352672 @default.
• W4379336031 hasConceptScore W4379336031C2911057145 @default.
• W4379336031 hasConceptScore W4379336031C3019882237 @default.
• W4379336031 hasConceptScore W4379336031C502942594 @default.
• W4379336031 hasConceptScore W4379336031C55493867 @default.
• W4379336031 hasConceptScore W4379336031C71924100 @default.
• W4379336031 hasConceptScore W4379336031C86803240 @default.
• W4379336031 hasConceptScore W4379336031C8891405 @default.
• W4379336031 hasIssue "16_suppl" @default.
• W4379336031 hasLocation W43793360311 @default.
• W4379336031 hasOpenAccess W4379336031 @default.
• W4379336031 hasPrimaryLocation W43793360311 @default.
• W4379336031 hasRelatedWork W2546607321 @default.
• W4379336031 hasRelatedWork W2592052792 @default.
• W4379336031 hasRelatedWork W2809077554 @default.
• W4379336031 hasRelatedWork W2904110710 @default.
• W4379336031 hasRelatedWork W2961042511 @default.
• W4379336031 hasRelatedWork W3028814175 @default.
• W4379336031 hasRelatedWork W3202746846 @default.
• W4379336031 hasRelatedWork W4291367166 @default.
• W4379336031 hasRelatedWork W4295037691 @default.
• W4379336031 hasRelatedWork W4360983034 @default.
• W4379336031 hasVolume "41" @default.
• W4379336031 isParatext "false" @default.
• W4379336031 isRetracted "false" @default.
• W4379336031 workType "article" @default.